Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Research & Development is the aggregate amount of research and development expenses during the year. Jenscare Scientific Co's Research & Development for the
six
months ended in Dec. 2025 was HK$104.64 Mil.
Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was HK$201.80 Mil.
Jenscare Scientific Co (HKSE:09877) Research & Development Explanation
If competitive advantage is created by a patent or tech advantage, at some point it will disappear.
High R&D usually dictates high SG&A which threatens the competitive advantage.
Jenscare Scientific Co Research & Development Related Terms
Jenscare Scientific Co Research & Development Historical Data
* Premium members only.
The historical data trend for Jenscare Scientific Co's Research & Development can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jenscare Scientific Co Research & Development Chart
Jenscare Scientific Co Research & Development Calculation
This is the expense the company spent on research and development.
Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$201.80 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Research & Development of HK$201.80 Mil mean?
Jenscare Scientific Co (HKSE:09877) has a Research & Development of HK$201.80 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Jenscare Scientific Co and its competitors.
Is Jenscare Scientific Co's Research & Development too high?
Jenscare Scientific Co's current Research & Development is HK$201.80 Mil. Overall, Jenscare Scientific Co has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Jenscare Scientific Co's Research & Development compare to ABT and SYK?
Jenscare Scientific Co's Research & Development of HK$201.80 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Jenscare Scientific Co and its competitors. Jenscare Scientific Co's current Research & Development is HK$201.80 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jenscare Scientific Co stock overvalued right now?
Jenscare Scientific Co (HKSE:09877) has a current Research & Development of HK$201.80 Mil. The current Research & Development is HK$201.80 Mil. Jenscare Scientific Co's overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Jenscare Scientific Co (HKSE:09877), the current Research & Development is HK$201.80 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Jenscare Scientific Co Ltd is engaged in the manufacturing, research, and development of medical devices. The company develops interventional products for the treatment of structural heart disease. The company's core products include LuX-Valve and Ken-Valve. LuX-Valve is a transcatheter tricuspid valve replacement system designed for patients with severe tricuspid regurgitation and high surgical risk. Ken-Valve is designed for the treatment of severe aortic regurgitation or combined with aortic stenosis. The company also develops product candidates for the treatment of mitral valve diseases and medical devices for the treatment of heart failure. Geographically, the company generates the majority of its revenue from the Chinese mainland.
33GF Score
Get the complete analysis for HKSE:09877
Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:09877 has been successfully added to your 
